Whitepaper: Profiling oncology candidates
Posted: 9 February 2021 | Eurofins Discovery | No comments yet
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
In this whitepaper, we describe a profiling strategy that includes both in vitro and in vivo approaches to characterise sorafenib, an ATP-competitive multi-kinase inhibitor with clinical applications in multiple cancer types. Data for vemurafenib, an anti-neoplastic B-Raf kinase inhibitor, is also included to highlight how profiling compounds can shed light onto potentially different applications in the clinic.
Related content from this organisation
- Human iPSC-derived cardiomyocytes for cardiac proarrhythmic risk assessment
- Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts
- Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes
- Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes
- Hit discovery for GPCRs: HTS or virtual screens?
Related topics
Assays, Biopharmaceuticals, Disease research, Hit-to-Lead, In Vitro, In Vivo, Screening, Targets
Related organisations
Eurofins Discovery
